Get the Stockscreener App
3.73
2.61%
-0.10
After Hours:
3.73
Plus Therapeutics Inc stock is traded at $3.73, with a volume of 48,741.
It is down -2.61% in the last 24 hours and down -11.19% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$3.83
Open:
$3.83
24h Volume:
48,741
Relative Volume:
0.29
Market Cap:
$25.68M
Revenue:
$5.21M
Net Income/Loss:
$-26.35M
P/E Ratio:
-0.1162
EPS:
-32.0862
Net Cash Flow:
$-20.84M
1W Performance:
-2.61%
1M Performance:
-11.19%
6M Performance:
+1,461%
1Y Performance:
+604.04%
1-Day Range:
$3.7001
$3.91
1-Week Range:
$3.7001
$4.08
52-Week Range:
$0.129
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
3.73 | 26.37M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Lake Street | Buy |
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Plus Therapeutics Inc (PSTV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Plus Therapeutics Inc (PSTV) Income Statement - TradingKey
Plus Therapeutics Inc (PSTV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PSTV|Plus Therapeutics Inc|Price:3.830|Chg%:+0.050 - TradingKey
PLUS THERAPEUTICS Inc. (PSTV) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Plus Therapeutics Inc. R (XMP1.DU) stock price, news, quote and history - Yahoo Finance UK
Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Plus Therapeutics Inc (PSTV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Plus Therapeutics, Inc. (PSTV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Plus Therapeutics secures regional coverage for... - Pluang
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - The Manila Times
CNSide Diagnostics signs coverage deal with Medical Mutual - Investing.com
CNSide Diagnostics signs coverage deal with Medical Mutual By Investing.com - Investing.com Canada
Plus Therapeutics Secures Regional Coverage Agreement with - GlobeNewswire
Plus Therapeutics Inc. R (XMP1.DU) valuation measures and financial statistics - Yahoo Finance UK
PLUS THERAPEUTICS INC (PSTV) Stock Chart - ChartMill
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform - Sahm
Plus Therapeutics partners with GTC on CSF diagnostic platform - Investing.com UK
Plus Therapeutics partners with GTC on CSF diagnostic platform By Investing.com - Investing.com Nigeria
Plus Therapeutics (PSTV) Forms Partnership for Advanced Biomarker Profiling - GuruFocus
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring - Sahm
NCCN updates guidelines for leptomeningeal metastases diagnosis - Investing.com UK
Plus Therapeutics (PSTV) Updates NCCN Guidelines for CNS Cancers - GuruFocus
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines - GlobeNewswire
Guidelines call for spinal-fluid checks every 4–8 weeks during therapy - Stock Titan
PLUS THERAPEUTICS (PSTV) Surges 7%: Biotech Momentum Testing Key ResistanceFair Value Gap - DonanımHaber
Plus Therapeutics subsidiary enrolls in Medicare program - Investing.com
PSTV Should I Buy - Intellectia AI
PLUS THERAPEUTICS Inc. (PSTV) Q1 2026 Earnings: Wider Loss Per Share Overshadows Clinical ProgressProfit Growth Outlook - dars.gov.et
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J - Moomoo
Plus Therapeutics (PSTV) CEO gains 16,439 shares from RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) director converts 922 RSUs into common stock - Stock Titan
Plus Therapeutics (NASDAQ: PSTV) director gains 922 shares via RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) CFO converts RSUs into 2,985 common shares - Stock Titan
[Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Plus Therapeutics provides mid-year business update including corporate rebranding - MSN
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY - Investing.com UK
Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress - marketscreener.com
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) - Yahoo Finance
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY By Investing.com - Investing.com South Africa
Plus Therapeutics to Rebrand as Cerenome, Affirm 2026 Guidance and Report CNSide Commercial Progress - Quiver Quantitative
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding - GlobeNewswire
Price to earnings forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to EBITDA forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to EBIT forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Price to sales forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to revenue forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Index - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Growth Benchmark - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell Microcap Index - marketscreener.com
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):